Skip to main content
SpringerLink
Log in

Adherence: The Great Masquerader of Treatment-Resistance

  • Chapter
  • First Online:
Handbook of Treatment-resistant Schizophrenia

  • 1047 Accesses

Abstract

Adherence or compliance with a medication regimen is generally defined as the extent to which patients take medications as prescribed. The term “compliance” has fallen out of favor as it implies a power imbalance between clinician and patient. The pejorative labeling of a patient as “noncompliant” is not therapeutically productive. The term “adherence” is more consistent with a shared decision-making model and the establishment of a therapeutic alliance. It is common in research studies of adherence to categorize a patient as adherent if they take at least 80 % of their prescribed medication.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487–497.

    Google Scholar 

  2. Velligan DI, Weiden PJ, Sajatovic M, et al. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry. 2009;70(suppl 4):1–46.

    Google Scholar 

  3. Velligan DI, Wang M, Diamond P, et al. Relationships among subjective and objective measures of adherence to oral antipsychotic medications. Psychiatr Serv. 2007;58:1187–1192.

    Google Scholar 

  4. Velligan DI, Lam YW, Glahn DC, et al. Defining and assessing adherence to oral antipsychotics: a review of the literature. Schizophr Bull. 2006;32:724–742.

    Google Scholar 

  5. Valenstein M, Ganoczy D, McCarthy JF, Kim HM, Lee TA , Blow FC . Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review. J Clin Psychiatry. 2006;67:1542–1550.

    Google Scholar 

  6. Byerly MJ, Nakonezny PA, Lescouflair E. Antipsychotic medication adherence in schizophrenia. Psychiatr Clin North Am. 2007;30:437–452.

    Google Scholar 

  7. Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry. 2002;63:1121–1128.

    Google Scholar 

  8. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002;63:892–909.

    Google Scholar 

  9. Weiden P, Rapkin B, Zygmunt A, Mott T, Goldman D, Frances A. Postdischarge medication compliance of inpatients converted from an oral to a depot neuroleptic regimen. Psychiatr Serv. 1995;46:1049–1054.

    Google Scholar 

  10. Weiden PJ. Understanding and addressing adherence issues in schizophrenia: from theory to practice. J Clin Psychiatry. 2007;68(suppl 14):14–19.

    Google Scholar 

  11. Frank AF , Gunderson JG. The role of the therapeutic alliance in the treatment of schizophrenia. Relationship to course and outcome. Arch Gen Psychiatry. 1990;47:228–236.

    Google Scholar 

  12. Lincoln TM , Lüllmann E, Rief W. Correlates and long-term consequences of poor insight in patients with schizophrenia. A systematic review. Schizophr Bull. 2007;33:1324–1342.

    Google Scholar 

  13. Citrome L. Treatment-refractory schizophrenia: what is it and what has been done about it? Neuropsychiatry. 2011;1:325–347.

    Google Scholar 

  14. Weiden PJ, Buckley PF. Reducing the burden of side effects during long-term antipsychotic therapy: the role of “switching” medications. J Clin Psychiatry. 2007;68(suppl 6):14–23.

    Google Scholar 

  15. Tandon R. Safety and tolerability: how do newer generation “atypical” antipsychotics compare? Psychiatr Q. 2002;73:297–311.

    Google Scholar 

  16. Ascher-Svanum H, Zhu B, Faries D, Lacro JP, Dolder CR . A prospective study of risk factors for nonadherence with antipsychotic medication in the treatment of schizophrenia. J Clin Psychiatry. 2006;67:1114–1123.

    Google Scholar 

  17. Regier DA , Farmer ME , Rae DS , et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA ) Study. JAMA. 1990;264:2511–2518.

    Google Scholar 

  18. Lybrand J, Caroff S. Management of schizophrenia with substance use disorders. Psychiatr Clin North Am. 2009;32:821–833.

    Google Scholar 

  19. Lieberman JA, Stroup TS , McEvoy JP, et al; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE ) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209–1223.

    Google Scholar 

  20. Van Dorn RA, Desmarais SL, Scott Young M, Sellers BG, Swartz MS. Assessing illicit drug use among adults with schizophrenia. Psychiatry Res. 2012;200:228–236.

    Google Scholar 

  21. Kerfoot KE , Rosenheck RA , Petrakis IL, et al; CATIE Investigators. Substance use and schizophrenia: adverse correlates in the CATIE study sample. Schizophr Res. 2011;132:177–182.

    Google Scholar 

  22. Velligan DI, Weiden PJ, Sajatovic M, et al. Assessment of adherence problems in patients with serious and persistent mental illness: recommendations from the Expert Consensus Guidelines. J Psychiatr Pract. 2010;16:34–45.

    Google Scholar 

  23. Weiden PJ. Why did John Nash stop his medication? J Psychiatr Pract. 2002;8:386–392.

    Google Scholar 

  24. McCabe R, Heath C, Burns T, Priebe S. Engagement of patients with psychosis in the consultation: conversation analytic study. BMJ. 2002;325:1148–1151.

    Google Scholar 

  25. Velligan D, Diamond PM, Mintz J, et al. The use of individually tailored environmental supports to improve medication adherence and outcomes in schizophrenia. Schizophr Bull. 2008;34:483–493.

    Google Scholar 

  26. McEvoy JP. Risks versus benefits of different types of long-acting injectable antipsychotics. J Clin Psychiatry. 2006;67(suppl 5):15–18.

    Google Scholar 

  27. Kane JM, Leucht S, Carpenter D, Docherty JP. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry. 2003;64(suppl 12):5–19.

    Google Scholar 

  28. Leucht C, Heres S, Kane JM et al. Oral versus depot antipsychotic drugs for schizophrenia - a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res. 2011;127:83–92.

    Google Scholar 

  29. Patel MX , De Zoysa N, Baker D, David AS . Antipsychotic depot medication and attitudes of community psychiatric nurses. J Psychiatr Ment Health Nurs. 2005;12:237–244.

    Google Scholar 

  30. Citrome L. Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection. Patient Prefer Adherence. 2009;3:345–355.

    Google Scholar 

  31. Citrome L. Paliperidone palmitate – review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication. Int J Clin Pract. 2010;64:216–239.

    Google Scholar 

  32. Citrome L, Levine J, Allingham B. Utilization of depot neuroleptic medication in psychiatric inpatients. Psychopharmacol Bull. 1996;32:321–326.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY, USA

    Leslie Citrome

Authors
  1. Leslie Citrome
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Healthcare

About this chapter

Cite this chapter

Citrome, L. (2013). Adherence: The Great Masquerader of Treatment-Resistance. In: Handbook of Treatment-resistant Schizophrenia. Springer Healthcare, Tarporley. https://doi.org/10.1007/978-1-908517-88-3_3

Download citation

  • DOI: https://doi.org/10.1007/978-1-908517-88-3_3

  • Published:

  • Publisher Name: Springer Healthcare, Tarporley

  • Print ISBN: 978-1-908517-86-9

  • Online ISBN: 978-1-908517-88-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation